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INTRODUCTION
Fluorescein angiography is a technique used for the interpretation of
ocular diseases. It allows sequential visualization of the blood flow simulta-
neously in the retina, choroid and iris, and it gives diagnostic support to
clinical impressions based on alterations in fluid dynamics resulting from
ocular disease processes(1-2).
This procedure is considered relatively safe and although numerous
adverse reactions have been reported in literature, the most frequent are
mild, such as nausea and vomiting(3-5). The incidence of these adverse
reactions has varied among the authors (2%-14%)(6-8).
Nausea and vomiting can occur independently, but they are so strictly
associated that it is possible to presume that they are mediated by the same
neural path and can be considered a set(9-10). The efficient treatment of nausea
and vomiting depends on the correlation with the basic cause. Most pharma-
cologic therapies are reactive instead of preventive. The benefit of antiemetic
agents varies according to the etiology of the symptoms, of the response of
the patient to the medication and the occurrence of side effects(9-10).
The dopamine receptors in the stomach seem to mediate the inhibition
of the gastric motility that occurs during nausea and vomiting, and these
receptors can indicate an action site for the antiemetics antagonists of the
dopamine receptor. They also participate in the consequences that result in
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Purposes: To determine the efficacy of bromopride in the prophylaxis of
nausea during fluorescein angiography, when compared with a placebo.
Methods: The study was a double-masked random clinical trial, between
December of 2004 and April of 2005. Examinations were performed with
20% intravenous fluorescein sodium in a single dose of 2.5 ml. The
patients were divided into two groups: group 1, patients who received
a 2 ml intravenous dose of 5 mg/ml bromopride and group 2, patients who
received a 2 ml intravenous dose of 0.9% sodium chloride (placebo), both
20 minutes before the dye injection. Cases of nausea were observed
during and after the examination. Results: 352 patients were enrolled, 176
in each group. Cases of nausea were observed in 12 (6.8%) patients of
the bromopride group and in 11 (6.3%) patients of the placebo group
(p<0.829 - relative risk=1.05). Conclusion: Bromopride did not prevent
the occurrence of nausea in fluorescein angiography, when compared
with a placebo.
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a relaxation of the upper part of the stomach and retardation of
the gastric emptiness in response to the gastric distension by
food. This forms the basis for the use of dopaminergic antago-
nists as prokinetic agents(9-10).
Bromopride is an antagonist of dopamine. The main action
mechanism results from esophagus gastric duodenal transit
acceleration and inhibition of the gastric relaxation determined
by dopamine, as well as the increase in tonicity of the inferior
sphincter of the esophagus. It also has a central level of antie-
metic action in the hypothalamus, acting on D2 receptors(11-12).
Nausea results in discomfort for the patient and makes the
capture of images difficult in the initial phase of fluorescein
angiography, there being cases of subretinal hemorrhage due
to Valsalva maneuver(1,13).
The objective of this study was to determine the efficacy
of bromopride in the prophylaxis of nausea during fluorescein
angiography, when compared with a placebo.
METHODS
Patient and medical procedures
This study was a double-masked random clinical trial car-
ried out at the Federal University of Pernambuco. The medical
center’s Human Subjects Committee approved the study pro-
tocol (protocol 229/2005).
Patients scheduled to undergo fluorescein angiography
were recruited between December 2004 and April 2005. Patients
were excluded from the study if they were pregnant, or made use
of dopaminergics, antihistaminic antagonists, antiemetics, cor-
ticosteroids or immunosuppressants. All patients provided a
written informed consent before enrollment in the study.
For the examination 20% fluorescein sodium dye (Ophthal-
mos®) was used at a single 2.5 ml dose, injected into the
cubital vein, with a manual infusion rate of approximately 1 ml
per second.
For the patients who agreed to participate in the study, the
scheduled fluorescein angiography was randomly assigned to
one of two groups: 1) to be preceded by a 2 ml intravenous dose
of 5 mg/ml bromopride or 2) to be preceded by a 2 ml intrave-
nous dose of 0.9% sodium chloride (placebo), both 20 minutes
before the dye injection. Randomization was performed in
blocks of four. Patients were randomly assigned to one of the
two study groups until two patients had been assigned to each
one of the two groups, completing the block of four. Randomi-
zation was performed by computer at the time of enrollment.
The syringes with bromopride or saline solution were pre-
pared by a nursing technician, before the procedure, and
identified by a record number for posterior evaluation of the
results. It was not possible to visually distinguish the content
from the syringe; thus, the doctors and the patients did not
know which substance was being applied. Mean age, sex,
prevalence of diabetes and arterial hypertension of both
groups were compared with the purpose to know if the groups
were well balanced. Diabetes and arterial hypertension were
selected because they are the most prevalent coexisting illnes-
ses in fluorescein angiography patients(14-15).
Data collection
The data had been collected through a specific file, which
contained history and physical examination of the patient,
filled in by the anesthetist at the moment of clinical evaluation.
The definition of nausea used in the study was a vague,
intensely disagreeable sensation of sickness or queasiness
that may or may not be followed by vomiting. Nausea occur-
ring during the angiography had been registered in a file of
protocol by the ophthalmologist. Nausea occurring subse-
quently was collected by a standardized telephone interview
of the patient conducted by the study coordinator twelve
hours after the examination.
Sample size and statistical analysis
A minimum sample of 340 patients (170 per group) was
planned. Assuming a 7% incidence of nausea in the placebo
group, this sample would allow 80% power of being able to
detect a difference as small as 6.5% in the bromopride group. As
a parameter of central trend and dispersion for the data, means
and standard deviation (SD) had been determined. Tests were
made to detect differences between variables, using chi-square
test and relative risk (RR) for categorical variables, and t test for
quantitative variables. The results of this analysis were consi-
dered significant if p value was less than 0.05.
RESULTS
We enrolled 352 patients scheduled to undergo fluores-
cein angiography between December 2003 and April 2004. The
sample consisted of 176 patients assigned to each group. The
two groups were well balanced in terms of age, with a mean
age of 57.2 years (SD=11.7 years) in the bromopride group and
58.6 years (SD=14.4 years) in the placebo group (p=0.398). The
groups were also well balanced with respect to sex and
prevalence of diabetes and arterial hypertension (Table 1).
Nausea was observed in 12 (6.8%) patients of the bromo-
pride group and in 11 (6.3%) patients of the placebo group
(p<0.829 - RR=1.05 [0.70<RR<1.57]) (Table 2). All cases of
nausea occurred during the angiography.
Table 1. Characteristics of the patients and coexisting illness,
according to the group assignment, fluorescein angiography study,
Recife, 2005
Characteristics Bromopride Placebo p
(n=176) (n=176)
Age (years) 57.2±11.7 58.6±14.4 0.398*
Number of patients (%)
Female 99 (56.2) 93 (52.8) 0.520†
Arterial hypertension 77 (43.7) 73 (41.5) 0.666†
Diabetes 65 (36.9) 69 (39.2) 0.660†
*t test; †chi-square test
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DISCUSSION
The frequency of nausea in the present study was 6.53%,
which is in accordance with the literature(6-8). The pathophysio-
logy involves the activation of chemoreceptor of the vomiting
nervous center, located in the postrema area, posterior region of
the fourth ventricle, alternatively as well as through other stron-
ger influences of the central nervous system (for example, limbic
system) that function as primary detectors of the emetic stimu-
lation and induce vomiting through integration with the pos-
trema area, vagal nerve or vestibular system(9-10,12,16).
Random clinical trials were carried out evaluating the influ-
ence of the concentration and the temperature of the dye in
the prophylaxis of nausea in fluorescein angiography. A diffe-
rence in the incidence of nausea between 10% and 25% con-
centrations of this dye was not observed and the 25% solu-
tion resulted in examinations of better quality(17). In addition, a
reduction of the incidence of nausea with the heating of the
contrast was not observed(18).
Only two random clinical trials exist to discuss the use of
medicines for nausea and vomiting prophylaxis in fluorescein
angiography, where granisetron and metoclopramide have
respectively been used(19-20).
Some authors carried out a study with 120 patients compa-
ring oral granisetron and a placebo and they observed 3 (5%)
cases of vomiting in the placebo group and none with this
medication. Despite the small sample, these authors sugges-
ted granisetron would be indicated for vomiting prophylaxis in
fluorescein angiography(19). Granisetron is a selective antago-
nist of the 5-HT
3
 receptor of 5-hydroxytryptamine and is usually
indicated for nausea prophylaxis associated with a cytostatic
therapy. However its use is associated with a larger incidence
of hepatocellular neoplasia(21).
Some authors carried out a study with 100 patients compa-
ring intravenous metoclopramide and a placebo and observed
11 (22%) cases of nausea or vomiting in the placebo group and
3 (6%) with this medication(20). This study presented the limita-
tion that the incidence of nausea in the placebo group was
higher than that observed in literature(6-8), a fact that was explai-
ned by the authors as a result of the used methodology where
the patient was stimulated to communicate any evidence of
nausea(20). Metoclopramide constitutes the archetype of selec-
tive antagonists of dopamine, called substitute benzamide and
has a powerful peripheral cholinergic effect that intensifies
gastric emptiness. However, the collateral neurological effects
are frequent, as well as muscular spasms, trembling, Parkinso-
nism and visual disturbance(10,12,19). The main advantage of
bromopride in relation to metoclopramide is the lower incidence
of neurological side effect, mainly extrapyramidal reactions(11).
Bromopride is used at a large scale because of its effecti-
veness in the treatment of nausea and vomiting, being consi-
dered safe also in children, pregnant women and elderly
people(22-24). Its use in the prophylaxis of nausea induced by
medicines was also studied. A research on women who deve-
loped symptoms of digestive intolerance caused by medicines
demonstrated that bromopride was efficient in the prophylaxis
of these symptoms(25).
In this study, the use of the bromopride before the fluores-
cein angiography did not decrease the incidence of nausea. A
possible explanation for the inefficacy of the bromopride in
the prophylaxis of nausea would be the insufficient time for
the drug to start acting, however, after intravenous adminis-
tration, drug bioavailability is immediate and a phase of initial
distribution occurs during a short period of time (5-10 minu-
tes) and the half-life is 3 hours(11).
The results suggested that the use of bromopride as prophy-
laxis for nausea in fluorescein angiography is not a procedure
that should be stimulated. However, it is not possible to discard
its utility in the treatment of already symptomatic patients.
Further studies will be necessary to confirm these findings.
CONCLUSION
In this study, bromopride did not prevent the occurrence
of nausea in fluorescein angiography, when compared with a
placebo.
RESUMO
Objetivos: Determinar a eficiência da bromoprida na profilaxia
de náuseas na angiofluoresceinografia, quando comparada a
um placebo. Métodos: O estudo foi um ensaio clínico aleatório
duplo-mascarado, entre dezembro de 2004 e abril de 2005. Os
exames foram realizados com fluoresceína sódica a 20% intra-
venosa em dose única de 2,5 ml. Os pacientes foram divididos
em dois grupos: grupo 1, pacientes que receberam 10 mg/ 2 ml
de bromoprida via intravenosa e o grupo 2, pacientes que
receberam uma dose 2 ml de cloreto de sódio a 0,9% (placebo),
ambos 20 minutos antes da injeção do contraste. Foram regis-
trados os casos de náusea durante e após o exame. Resulta-
dos: Foram selecionados 352 pacientes, 176 em cada grupo.
Foram registrados casos de náusea em 12 (6,8%) pacientes do
grupo da bromoprida e 11 (6,3%) pacientes do grupo placebo
(p<0,829 - risco relativo=1,09). Conclusão: Neste estudo a
bromoprida não preveniu a ocorrência de náuseas na angio-
fluoresceinografia, quando comparada a um placebo.
Table 2. Incidence of nausea in patients, according to the group
assignment, fluorescein angiography study, Recife, 2005
Medication
Bromopride Placebo
(n=176) (n=176)
Nausea n % n % p RR*
Present 012 06,8 011 06,3 0,83† 1,05
Absentee 164 93,2 165 93,7 (0,70<RR<1,57)
*RR= relative risk; †chi-square test
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